Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Stock Holdings Lifted by Avoro Capital Advisors LLC

Avoro Capital Advisors LLC raised its stake in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 34.7% during the 4th quarter, HoldingsChannel reports. The firm owned 14,555,555 shares of the company’s stock after acquiring an additional 3,747,475 shares during the period. Centessa Pharmaceuticals accounts for 3.5% of Avoro Capital Advisors LLC’s portfolio, making the stock its 10th biggest position. Avoro Capital Advisors LLC owned about 0.10% of Centessa Pharmaceuticals worth $364,034,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. TD Waterhouse Canada Inc. purchased a new position in shares of Centessa Pharmaceuticals in the 4th quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $36,000. Wells Fargo & Company MN boosted its stake in shares of Centessa Pharmaceuticals by 42.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after buying an additional 1,008 shares in the last quarter. Knott David M Jr purchased a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $100,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Centessa Pharmaceuticals by 26.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock valued at $117,000 after buying an additional 979 shares in the last quarter. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, insider Karen M. Anderson sold 41,076 shares of the business’s stock in a transaction on Thursday, March 26th. The stock was sold at an average price of $30.12, for a total value of $1,237,209.12. Following the completion of the transaction, the insider directly owned 62,085 shares of the company’s stock, valued at $1,870,000.20. The trade was a 39.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 4.09% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. Lifesci Capital downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 1st. Leerink Partners downgraded Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and lifted their price target for the company from $36.00 to $40.00 in a research note on Wednesday, April 1st. Stephens downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Wells Fargo & Company downgraded Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $35.00 to $42.00 in a research note on Monday, April 20th. Finally, Needham & Company LLC downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Four analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $41.33.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA stock opened at $39.75 on Wednesday. The stock has a fifty day moving average price of $39.65 and a 200 day moving average price of $31.04. The stock has a market cap of $6.15 billion, a PE ratio of -22.21 and a beta of 1.11. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $12.30 and a 1 year high of $40.26. The company has a debt-to-equity ratio of 0.23, a quick ratio of 9.53 and a current ratio of 9.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.14). Sell-side analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current fiscal year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical?stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision?making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.